Alzheimer’s affects over seven million Americans—a number expected to double by 2050. New FDA-approved drugs and early-detection blood tests give families hope, but government red tape still stands in the way. The Market Institute believes patients and doctors—not bureaucrats—should decide when to use lifesaving innovations. Empowering access to modern treatments isn’t just good policy—it’s the compassionate choice.
The European Union has long been a source of both classical liberal ideas and expansive government regulation. Today, the EU is increasingly exporting its regulatory model beyond its borders—including policies that threaten free speech online. Read more…
A new column by The Market Institute President Charles Sauer published in RealClearMarkets examines how outdated tax policy is quietly worsening America’s housing affordability crisis — and how a simple reform could help free up Read more…
The Market Institute and the Center for a Free Economy (CFE) led a coalition of free-market leaders and organizations urging congressional leadership to pass the More Homes on the Market Act (H.R. 1340 / S. Read more…
The intersection of antitrust enforcement and free speech is once again at the center of a growing policy debate in Washington. In a new RealClearMarkets column, Market Institute President Charles Sauer examines the Federal Trade Read more…
In a recent column for RealClearMarkets, Charles Sauer, President of The Market Institute, argues that while Lina Khan may be gone from the Federal Trade Commission, the politicization of antitrust enforcement remains very much alive. Read more…
Healthcare is intensely personal, especially when devastating diagnoses arrive. Yet too often, a system weighed down by regulation and bureaucracy compounds that pain, forcing patients and families to navigate life-altering decisions without the support or Read more…
6151 Fuller Court #8
Alexandria, VA 22310
The Market Institute
info@marketinstitute.org